CDK12 Gene Inactivation Identified as Driver of Rare Aggressive Ovarian Cancer

Researchers have identified the inactivation of the CDK12 gene as a key driver behind a rare and aggressive form of ovarian cancer. The study, published on June 9, 2025, provides insights into the genetic mechanisms underlying this disease and suggests potential avenues for therapeutic intervention.

The findings highlight how mutations or loss of function in the CDK12 gene contribute to the development and progression of certain ovarian cancers. This gene plays an essential role in regulating DNA repair processes, and its disruption can lead to genomic instability—a hallmark of many aggressive cancers. By pinpointing CDK12 inactivation as a critical factor, scientists aim to better understand tumor behavior and explore targeted treatment strategies that address this specific genetic alteration.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 9, 2025

Related posts:

European Biosimilar Market to Reach €10.4 Billion by 2025, Transforming Generic Drug Industry Aging Immune Systems Linked to Higher RSV Hospitalization Risk: Study Details Correlation Novo Nordisk Falls Behind Eli Lilly in Obesity Drug Market Amid Conservative R&D Approach Geospatial Mapping Reveals Pharmacy Deserts Impacting Access to Medications Across the United States

Author

Mark Chiang